Over US$2.8 billion and 15 years have been spent on each drug development, but less than 1% of drug candidates get approved for cancer treatment.

Single-cell drug screening enables researchers and scientists to analyse tumor heterogeneity, pharmacogenomics, and hidden mechanisms in drug resistance, which are masked by conventional cell population studies and animal testing. This will provide unprecedented resolution for Precision Oncology Research, New Drug Development, and Personalized Treatment Prediction for all cancer patients.